Point72 Europe London LLP Sells 34,903 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Point72 Europe London LLP reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 33.1% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 70,494 shares of the biopharmaceutical company’s stock after selling 34,903 shares during the quarter. Point72 Europe London LLP’s holdings in Gilead Sciences were worth $6,512,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Pallas Capital Advisors LLC grew its holdings in Gilead Sciences by 4.0% during the fourth quarter. Pallas Capital Advisors LLC now owns 8,150 shares of the biopharmaceutical company’s stock valued at $753,000 after purchasing an additional 314 shares during the period. Accurate Wealth Management LLC grew its stake in shares of Gilead Sciences by 7.1% during the 4th quarter. Accurate Wealth Management LLC now owns 3,456 shares of the biopharmaceutical company’s stock worth $311,000 after acquiring an additional 230 shares during the period. San Luis Wealth Advisors LLC increased its holdings in Gilead Sciences by 3.3% in the 4th quarter. San Luis Wealth Advisors LLC now owns 9,885 shares of the biopharmaceutical company’s stock worth $913,000 after acquiring an additional 319 shares during the last quarter. Kathmere Capital Management LLC raised its stake in Gilead Sciences by 42.7% in the 4th quarter. Kathmere Capital Management LLC now owns 17,527 shares of the biopharmaceutical company’s stock valued at $1,619,000 after acquiring an additional 5,246 shares during the period. Finally, Park Avenue Securities LLC lifted its stake in shares of Gilead Sciences by 31.4% during the 4th quarter. Park Avenue Securities LLC now owns 28,753 shares of the biopharmaceutical company’s stock valued at $2,656,000 after buying an additional 6,878 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at $19,977,938.37. This represents a 9.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold a total of 22,929 shares of company stock valued at $2,644,895 in the last ninety days. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Down 3.0%

GILD stock opened at $98.38 on Thursday. The business’s 50-day moving average is $106.33 and its two-hundred day moving average is $99.50. The company has a market cap of $122.50 billion, a price-to-earnings ratio of 265.89, a P/E/G ratio of 0.71 and a beta of 0.26. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The company had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter last year, the firm posted ($1.32) earnings per share. The firm’s revenue was down .3% compared to the same quarter last year. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 3.21%. The ex-dividend date is Friday, June 13th. Gilead Sciences’s payout ratio is 66.53%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on GILD. Oppenheimer lowered their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, April 25th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 25th. DZ Bank raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a research note on Thursday, February 13th. Royal Bank of Canada raised their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research report on Wednesday, February 12th. Finally, BMO Capital Markets raised their price target on Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. Nine equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $110.55.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.